HUE058698T2 - 1-heterociklusos izokromanil vegyületek és analógok a CNS rendellenességek kezelésére - Google Patents

1-heterociklusos izokromanil vegyületek és analógok a CNS rendellenességek kezelésére

Info

Publication number
HUE058698T2
HUE058698T2 HUE16708262A HUE16708262A HUE058698T2 HU E058698 T2 HUE058698 T2 HU E058698T2 HU E16708262 A HUE16708262 A HU E16708262A HU E16708262 A HUE16708262 A HU E16708262A HU E058698 T2 HUE058698 T2 HU E058698T2
Authority
HU
Hungary
Prior art keywords
isochromanil
analogues
heterocyclic
compounds
treatment
Prior art date
Application number
HUE16708262A
Other languages
English (en)
Hungarian (hu)
Inventor
Linghong Xie
Philip Glyn Jones
Kerry L Spear
Noel Aaron Powell
Taleen G Hanania
Original Assignee
Sunovion Pharmaceuticals Inc
Pgi Drug Discovery Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc, Pgi Drug Discovery Llc filed Critical Sunovion Pharmaceuticals Inc
Publication of HUE058698T2 publication Critical patent/HUE058698T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE16708262A 2015-02-11 2016-02-11 1-heterociklusos izokromanil vegyületek és analógok a CNS rendellenességek kezelésére HUE058698T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11

Publications (1)

Publication Number Publication Date
HUE058698T2 true HUE058698T2 (hu) 2022-09-28

Family

ID=55456908

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16708262A HUE058698T2 (hu) 2015-02-11 2016-02-11 1-heterociklusos izokromanil vegyületek és analógok a CNS rendellenességek kezelésére

Country Status (22)

Country Link
US (4) US9856238B2 (enExample)
EP (2) EP4046995B1 (enExample)
JP (3) JP6657241B2 (enExample)
KR (1) KR102601972B1 (enExample)
CN (2) CN111925360B (enExample)
AU (1) AU2016219253C1 (enExample)
CA (1) CA2976095C (enExample)
CY (1) CY1125198T1 (enExample)
DK (1) DK3256466T3 (enExample)
EA (1) EA201791804A1 (enExample)
ES (2) ES2967643T3 (enExample)
HU (1) HUE058698T2 (enExample)
IL (1) IL253914B (enExample)
MX (2) MX371404B (enExample)
MY (1) MY188160A (enExample)
NZ (1) NZ735011A (enExample)
PH (1) PH12017501422A1 (enExample)
PL (1) PL3256466T3 (enExample)
PT (1) PT3256466T (enExample)
SG (2) SG10201806809QA (enExample)
UA (1) UA122222C2 (enExample)
WO (1) WO2016130796A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016219253C1 (en) * 2015-02-11 2022-12-08 Pgi Drug Discovery Llc 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders
CA2976092A1 (en) * 2015-02-11 2016-08-18 Sunovion Pharmaceuticals Inc. Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
IL271464B2 (en) 2017-06-30 2024-08-01 Chase Therapeutics Corp NK-1 antagonist compositions and methods for use in the treatment of depression
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
DE69912279T2 (de) 1998-06-30 2004-07-29 Eli Lilly And Co., Indianapolis 5-ht1f agonisten
SE9902267D0 (sv) 1999-06-16 1999-06-16 Astra Ab New compounds
EP1446396A1 (en) * 2001-11-08 2004-08-18 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
JP4738418B2 (ja) * 2004-12-21 2011-08-03 エフ.ホフマン−ラ ロシュ アーゲー クロマン誘導体及びcns障害の処置におけるその使用
JP2008538576A (ja) 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
JP2009524618A (ja) * 2006-01-27 2009-07-02 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置における2−イミダゾールの使用
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
PT3252057T (pt) 2009-12-04 2024-06-04 Sunovion Pharmaceuticals Inc Compostos multicíclicos e métodos de utilização dos mesmos
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
AR090557A1 (es) 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AU2013369649B2 (en) * 2012-12-31 2018-07-26 Sunovion Pharmaceuticals Inc. Heterocyclic compounds and methods of use thereof
AU2016219253C1 (en) * 2015-02-11 2022-12-08 Pgi Drug Discovery Llc 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders

Also Published As

Publication number Publication date
EA201791804A1 (ru) 2018-02-28
JP2020079282A (ja) 2020-05-28
NZ735011A (en) 2023-07-28
JP6657241B2 (ja) 2020-03-04
US9856238B2 (en) 2018-01-02
CN111925360B (zh) 2024-03-22
EP4046995A1 (en) 2022-08-24
ES2911910T3 (es) 2022-05-23
ES2967643T3 (es) 2024-05-03
US20190389845A1 (en) 2019-12-26
MY188160A (en) 2021-11-24
SG10201806809QA (en) 2018-09-27
MX371404B (es) 2020-01-29
EP4046995B1 (en) 2023-09-13
IL253914A0 (en) 2017-10-31
CN111925360A (zh) 2020-11-13
PT3256466T (pt) 2022-05-10
KR20170129730A (ko) 2017-11-27
JP2018505205A (ja) 2018-02-22
IL253914B (en) 2021-09-30
WO2016130796A1 (en) 2016-08-18
SG11201706515QA (en) 2017-09-28
AU2016219253B2 (en) 2020-10-01
BR112017017354A2 (pt) 2018-04-10
US20180093974A1 (en) 2018-04-05
US20170001987A1 (en) 2017-01-05
CA2976095A1 (en) 2016-08-18
JP7023994B2 (ja) 2022-02-22
PH12017501422A1 (en) 2018-03-19
PL3256466T3 (pl) 2022-05-23
AU2016219253A1 (en) 2017-09-21
MX2017010363A (es) 2018-05-04
EP4046995C0 (en) 2023-09-13
EP3256466B1 (en) 2022-04-06
CA2976095C (en) 2023-10-17
JP2022065050A (ja) 2022-04-26
UA122222C2 (uk) 2020-10-12
ES2911910T9 (es) 2022-08-12
US11192885B2 (en) 2021-12-07
US10336732B2 (en) 2019-07-02
CN107531674A (zh) 2018-01-02
CY1125198T1 (el) 2024-12-13
CN107531674B (zh) 2020-07-31
MX2020001157A (es) 2022-05-27
MX392664B (es) 2025-03-24
EP3256466B9 (en) 2022-07-27
DK3256466T3 (da) 2022-05-02
AU2016219253C1 (en) 2022-12-08
KR102601972B1 (ko) 2023-11-13
US20220185799A1 (en) 2022-06-16
EP3256466A1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
IL283258A (en) Treatment of hypoparathyroidism
IL247452A0 (en) Compounds for treatment of complement mediated disorders
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
HUE054042T2 (hu) Pirazolvegyületek és eljárás a vegyületek elõállítására és alkalmazásuk
LT3224269T (lt) Kompozicijos ir būdai, skirti cns sutrikimams gydyti
LT3261640T (lt) 5ht agonistai epilepsijos sutrikimų gydymui
IL253945B (en) kdm1a inhibitors to treat the disease
IL264143B (en) Processes for preparing olaparib
LT3250210T (lt) Kompozicijos ir būdai, skirti gydyti cns sutrikimus
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
HUE059158T2 (hu) Eljárás pridopidin elõállítására
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
HUE046509T2 (hu) Új vegyület és eljárás
DK3256466T3 (da) 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser
IL256103B (en) Compositions and methods for treating celiac sprue disease
IL253854B (en) Mebendazole polymorph for treatment and prevention of tumors
HUE064604T2 (hu) Menotropin meddõség kezelésére
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
HUE042043T2 (hu) Malária megelõzésére vagy kezelésére alkalmas triaminopiridin-vegyületek
PL3463328T3 (pl) Seladelpar do leczenia pierwotnego zapalenia dróg żółciowych
IL259674B (en) Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases
PL3484475T3 (pl) 1-Metylonikotynamid do leczenia choroby układu krążenia